World's Largest Review Finds Opioids Often No Better Than Placebo for Acute Pain

The most comprehensive review ever conducted on opioids for acute pain has reached a striking conclusion: for many common conditions, these powerful and widely prescribed drugs provide only small, short-lived benefits, and in some cases work no better than a placebo.

Researchers at the University of Sydney led the investigation, which pooled evidence from 59 systematic reviews covering more than 50 distinct acute pain conditions in both children and adults. The analysis examined the effectiveness and safety of commonly used opioids, including codeine, morphine, oxycodone and tramadol, and was published in the journal Drugs. The authors describe it as the strongest and most complete body of evidence assembled to date on how well opioids actually relieve sudden, short-term pain.

The findings challenge a long-held assumption in medicine that opioids are the most reliable option for acute pain. For a range of conditions, the drugs delivered only modest, time-limited relief: the review found small benefits for stomach pain, dental surgery, certain ear procedures, traumatic limb injuries, pain after childbirth, cesarean delivery and bunionectomy. But for other conditions, opioids performed no better than an inactive placebo, including some limb surgeries, the intense pain of kidney stones, recovery after tonsil removal, and pain in newborns on assisted breathing devices.

Alongside the limited benefits, the researchers documented meaningful harms. Patients taking opioids experienced higher rates of side effects, and the authors warned that physical dependence can begin after only a short period of use, a finding with particular weight given the addiction crisis that has been fueled in part by prescriptions written for acute pain. The combination of marginal effectiveness and tangible risk, they argue, calls into question the routine use of opioids in many everyday clinical situations.

Rather than calling for an outright ban, the team framed the review as a map of where opioids do and do not help, intended to guide doctors toward more targeted prescribing. In conditions where the drugs offer little advantage over safer alternatives such as anti-inflammatory medications or non-drug approaches, clinicians may be able to spare patients unnecessary exposure to the risks of dependence and side effects without sacrificing pain control.

The work arrives as health systems around the world continue to grapple with the fallout of decades of heavy opioid prescribing. By assembling the scattered evidence into a single, large-scale picture, the Sydney researchers say they hope to give physicians, patients and policymakers a clearer basis for deciding when these medications are truly warranted, and when they are not.